A randomized, double blind, placebo controlled, 4 period incomplete block cross over, multi center, multiple dose (7 days) dose-ranging study to assess the efficacy and safety of 4 doses of NVA237 [glycopyrrolate] in patients with stable COPD [chronic obstructive pulmonary disease], compared to seven days treatment with tiotropium (18microg once daily, open label) as an active control.

Trial Profile

A randomized, double blind, placebo controlled, 4 period incomplete block cross over, multi center, multiple dose (7 days) dose-ranging study to assess the efficacy and safety of 4 doses of NVA237 [glycopyrrolate] in patients with stable COPD [chronic obstructive pulmonary disease], compared to seven days treatment with tiotropium (18microg once daily, open label) as an active control.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 May 2016

At a glance

  • Drugs Glycopyrrolate (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Oct 2008 Results have been presented at the 18th Annual Congress of the European Respiratory Society according to a Sosei Group Corporation media release.
    • 07 Oct 2008 Results have been presented at the 18th Annual Congress of the European Respiratory Society.
    • 22 Dec 2007 Status change from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top